Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol

INTRODUCTION: Blood cholesterol is likely a risk factor for prostate cancer prognosis and use of statins is associated with lowered risk of prostate cancer recurrence and progression. Furthermore, use of statins has been associated with prolonged time before development of castration resistance (CR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Siltari, Aino, Riikonen, Jarno, Koskimäki, Juha, Pakarainen, Tomi, Ettala, Otto, Boström, Peter, Seikkula, Heikki, Kotsar, Andres, Tammela, Teuvo, Helminen, Mika, Raittinen, Paavo V, Lehtimäki, Terho, Fode, Mikkel, Østergren, Peter, Borre, Michael, Rannikko, Antti, Marttila, Timo, Salonen, Arto, Ronkainen, Hanna, Löffeler, Sven, Murtola, Teemu J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058683/
https://www.ncbi.nlm.nih.gov/pubmed/35487730
http://dx.doi.org/10.1136/bmjopen-2021-050264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058683/
https://www.ncbi.nlm.nih.gov/pubmed/35487730
http://dx.doi.org/10.1136/bmjopen-2021-050264

Ejemplares similares